Allergic Rhinoconjunctivitis clinical trials

Explore recruiting allergic rhinoconjunctivitis clinical trials.

Recruiting allergic rhinoconjunctivitis studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Allergic Rhinoconjunctivitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized, double-blind, placebo-controlled clinical trial to evaluate the optimal dose of Beltavac® with polymerized extract of grass pollen mixture in patients with allergic rhinoconjunctivitis associated or not with asthma.

Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial in parallel groups which evaluates the clinical efficacy and safety of immunotherapy with the purified major allergen Cup a 1, in patients with moderate/severe allergic rhino conjunctivitis with or without controlled asthma, sensitized to Cupressaceae

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy (Beltavac®) with Polymerized Allergenic Extract of a Mixture of Dermatophagoides and Blomia tropicalis in Patients with Allergic Rhinitis/rhinoconjunctivitis.

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A long-term, double-blind, randomised, placebo-controlled clinical trial to investigate the efficacy and safety of PQ Grass 27600 SU in children and adolescents with seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure

Slovakia, Czechia, Bulgaria, Romania, Poland, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis

Poland, Spain, Italy

Therapeutic use (Phase IV) EU CTIS Study details

A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma

Finland, Slovakia, Germany, Sweden, Austria, Romania +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Allergic Rhinoconjunctivitis trials by city

Allergic Rhinoconjunctivitis clinical trials

Recruiting allergic rhinoconjunctivitis studies right now

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

Also recruiting in Europe

Randomized, double-blind, placebo-controlled clinical trial to evaluate the optimal dose of Beltavac® with polymerized extract of grass pollen mixture in patients with allergic rhinoconjunctivitis associated or not with asthma.

A multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy (Beltavac®) with Polymerized Allergenic Extract of a Mixture of Dermatophagoides and Blomia tropicalis in Patients with Allergic Rhinitis/rhinoconjunctivitis.

A long-term, double-blind, randomised, placebo-controlled clinical trial to investigate the efficacy and safety of PQ Grass 27600 SU in children and adolescents with seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure

International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis

A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma

Allergic Rhinoconjunctivitis trials by city

Other conditions